INNOVIVA, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
INNOVIVA, INC. (INVA) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 12.19 million shares for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-03-17.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2022-03-17
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-09-30 was 12.19K shares, a 0.00% change year-over-year.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-06-30 was 12.19M shares, a 0.00% change year-over-year.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-03-31 was 12.19M shares, a 0.00% change year-over-year.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2020-09-30 was 12.19K shares, a 99.90% decline year-over-year.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 12.19M shares, a 0.00% change from fiscal 2020.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2020 was 12.19M shares, a 0.00% change from fiscal 2019.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 12.19M shares, a 0.00% change from fiscal 2018.
- INNOVIVA, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 12.19M shares, a 0.00% change from fiscal 2017.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|---|---|
| 2021-12-31 | 12.19M shares 10-K/A · filed 2022-03-17 | |||||
| 2021-09-30 | 12.19K shares 10-Q · filed 2021-10-27 | 12.19K shares 10-Q · filed 2021-10-27 | ||||
| 2021-06-30 | 12.19M shares 10-Q · filed 2021-07-29 | 12.19M shares 10-Q · filed 2021-07-29 | ||||
| 2021-03-31 | 12.19M shares 10-Q · filed 2021-04-28 | |||||
| 2020-12-31 | 12.19M shares 10-K/A · filed 2022-03-17 | |||||
| 2020-09-30 | 12.19K shares 10-Q · filed 2021-10-27 | 12.19M shares 10-Q · filed 2020-10-28 | 12.19K shares 10-Q · filed 2021-10-27 | 12.19M shares 10-Q · filed 2020-10-28 | ||
| 2020-06-30 | 12.19M shares 10-Q · filed 2021-07-29 | 12.19M shares 10-Q · filed 2021-07-29 | ||||
| 2020-03-31 | 12.19M shares 10-Q · filed 2021-04-28 | |||||
| 2019-12-31 | 12.19M shares 10-K/A · filed 2022-03-17 | |||||
| 2019-09-30 | 12.19M shares 10-Q · filed 2020-10-28 | 12.19M shares 10-Q · filed 2020-10-28 | ||||
| 2019-06-30 | 12.19M shares 10-Q · filed 2020-07-29 | 12.19M shares 10-Q · filed 2020-07-29 | ||||
| 2019-03-31 | 12.19M shares 10-Q · filed 2020-04-29 | |||||
| 2018-12-31 | 12.19M shares 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | 12.19M shares 10-Q · filed 2019-10-30 | 12.19M shares 10-Q · filed 2019-10-30 | ||||
| 2018-06-30 | 12.19M shares 10-Q · filed 2019-07-24 | 12.19M shares 10-Q · filed 2019-07-24 | ||||
| 2018-03-31 | 12.19M shares 10-Q · filed 2019-05-01 | |||||
| 2017-12-31 | 12.19M shares 10-K · filed 2020-02-19 | |||||
| 2017-09-30 | 12.19M shares 10-Q · filed 2018-10-31 | 12.19M shares 10-Q · filed 2018-10-31 | ||||
| 2017-06-30 | 12.19M shares 10-Q · filed 2018-07-26 | 12.19M shares 10-Q · filed 2018-07-26 | ||||
| 2017-03-31 | 12.19M shares 10-Q · filed 2018-05-04 | |||||
| 2016-12-31 | 12.54M shares 10-K · filed 2019-02-19 | |||||
| 2016-09-30 | 12.40M shares 10-Q · filed 2017-11-03 | 0.00 shares 10-Q · filed 2017-11-03 | ||||
| 2016-06-30 | 12.60M shares 10-Q · filed 2017-08-08 | 0.00 shares 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | 0.00 shares 10-Q · filed 2017-05-05 | |||||
| 2015-12-31 | 0.00 shares 10-K · filed 2018-02-23 | |||||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-02-28 | |||||
| 2012-09-30 | 6.67M shares 10-Q · filed 2012-10-31 | |||||
| 2012-06-30 | 6.67M shares 10-Q · filed 2013-08-01 | |||||
| 2012-03-31 | 6.67M shares 10-Q · filed 2013-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |